CSL Limited (ASX:CSL) Insider Megan Clark Acquires 132 Shares of Stock

CSL Limited (ASX:CSL) insider Megan Clark purchased 132 shares of the business’s stock in a transaction dated Wednesday, February 19th. The shares were purchased at an average cost of A$264.85 ($169.77) per share, with a total value of A$34,959.94 ($22,410.22).

CSL Stock Performance

The firm has a market cap of $77.43 billion, a PE ratio of 28.02, a P/E/G ratio of 1.29 and a beta of 0.32. The company has a debt-to-equity ratio of 64.46, a quick ratio of 1.68 and a current ratio of 1.86.

CSL Increases Dividend

The company also recently disclosed a Interim dividend, which will be paid on Tuesday, April 8th. Investors of record on Tuesday, April 8th will be issued a dividend of $2.073 per share. This is an increase from CSL’s previous Interim dividend of $1.83. The ex-dividend date is Sunday, March 9th. This represents a dividend yield of 0.81%. CSL’s dividend payout ratio (DPR) is 50.38%.

CSL Company Profile

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.